Loading...
Market
Number of New Collaborative Partners for HRO761 Research by End of 2025
4
Resolution / Starting Odds
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Press releases, official announcements from NIBR, Vividion, or partnering entities
Story
Breakthrough WRN Inhibitor HRO761 Targets MSI Cancers, Poised for Clinical Trials
Apr 24, 2024, 07:56 PM
Recent research has led to the discovery of a novel inhibitor, HRO761, targeting Werner Helicase (WRN), which shows synthetic lethality in microsatellite instability (MSI) cancers. This breakthrough, published in Nature, was achieved through chemoproteomic techniques that identified a covalent allosteric inhibitor of WRN. The research, spearheaded by NIBR and involving Vividion, marks a significant advancement in cancer treatment, particularly by transforming an ATP-competitive compound into an ATP-cooperative analogue. The development is poised for clinical testing to evaluate its effectiveness in human models of disease.
View original story
Similar markets
None • 25%
1-3 partnerships • 25%
4-6 partnerships • 25%
More than 6 partnerships • 25%
0-2 partnerships • 34%
3-5 partnerships • 33%
More than 5 partnerships • 33%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
0-5 companies • 25%
6-10 companies • 25%
11-20 companies • 25%
More than 20 companies • 25%
None • 33%
1-2 new partnerships • 33%
More than 2 new partnerships • 33%
None • 25%
1-2 partnerships • 25%
3-5 partnerships • 25%
More than 5 partnerships • 25%
200 partners • 25%
250 partners • 25%
300 partners • 25%
350 or more partners • 25%
No major partnerships • 25%
1-2 partnerships • 25%
3-4 partnerships • 25%
More than 4 partnerships • 25%
1-2 Partnerships/Acquisitions • 34%
3-5 Partnerships/Acquisitions • 33%
More than 5 • 33%
0-5 partnerships • 25%
6-10 partnerships • 25%
11-15 partnerships • 25%
More than 15 partnerships • 25%